Targeted radionuclide treatment for neuroendocrine tumors improves quality of life

(Society of Nuclear Medicine) Malignant neuroendocrine tumors, commonly called NETs, are easy to miss and associated with discouraging survival rates and poor quality of life. A study presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) shows how a novel peptide receptor radionuclide therapy (PRRT) is significantly improving patient wellbeing.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news